
==== Front
Cureus
Cureus
2168-8184
Cureus
2168-8184
Cureus Palo Alto (CA)

10.7759/cureus.67674
Obstetrics/Gynecology
Oncology
Mucinous Carcinoma in a Male: First Documented Case in Nicaragua
Muacevic Alexander
Adler John R
Altamirano Gilberto A Sr. 1
Romero Christopher K 1
Moreno Cabrera Catherine S 1
Aragón Conrado Lorenzo E 1
1 Medical Education, Hospital Militar Escuela "Dr. Alejandro Dávila Bolaños", Managua, NIC
Gilberto A. Altamirano Sr. gilbertoaltamirano010@gmail.com
24 8 2024
8 2024
16 8 e6767424 8 2024
Copyright © 2024, Altamirano et al.
2024
Altamirano et al.
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article is available from https://www.cureus.com/articles/275402-mucinous-carcinoma-in-a-male-first-documented-case-in-nicaragua
Breast malignancy in men is an exceedingly rare condition, representing a small fraction of all diagnosed breast cancer cases. The most common histological subtype is invasive ductal carcinoma, while the mucinous type is extremely rare. This pathology has a high mortality rate due to its poor prognosis and diagnosis in advanced stages, often initially overlooked with limited screening. Surprisingly, more men have died from breast cancer than from testicular cancer. This report details a case of invasive mucinous carcinoma in a 75-year-old male who presented with a five-week history of chronic non-productive cough and signs of pleural effusion. A breast magnetic resonance imaging (MRI) revealed a retroareolar breast tumor, and a second-look ultrasound confirmed the presence of a BI-RADS 4C solid nodule. Histopathological and immunohistochemical results were confirmed by ultrasound-guided tru-cut biopsy, identifying invasive mucinous carcinoma and luminal B (HER2+) subtype. Staging studies were negative for metastasis, and a modified radical mastectomy was performed, yielding favorable intraoperative findings. The incidental diagnosis in this patient highlights the necessity of comprehensive imaging in atypical presentations. Despite its rarity, awareness and early detection of mucinous carcinoma are essential for optimizing patient outcomes. This case also underscores the disparity in breast cancer outcomes between low gross domestic product (GDP) and high-GDP countries, emphasizing the need for improved access to diagnostic and therapeutic resources. Enhanced clinical awareness and early detection are crucial for improving outcomes in patients with rare histological subtypes, particularly in underserved regions.

multi-disciplinary teams
modified radical mastectomy
retro-areolar tumors
mucinous carcinoma
male breast cancer
==== Body
pmcIntroduction

Male breast cancer is a rare entity, constituting 0.2% of all male cancers and less than 1% of all new breast cancer cases [1]. Its incidence increases with age [2], with nearly 75% of cases occurring in men aged 60 years or older [3].

Pathologies that contribute to a hormonal profile with excess estrogen increase the risk of developing this neoplasm. Risk factors include excess estrogen, obesity, alcohol consumption, liver disease, and Klinefelter syndrome [4]. BRCA2 mutations are highly significant, with an incidence rate of up to 10% among male carriers [5,6].

Approximately 85% of male breast cancers are histologically invasive ductal carcinoma, while mucinous, medullary, papillary, tubular, and cribriform subtypes comprise less than 10% [1]. Treatment typically involves mastectomy and axillary lymph node dissection, with systemic therapy guidelines being similar for both sexes, yielding comparable response rates.

Case presentation

A 75-year-old male with a medical history notable for insulin-dependent diabetes mellitus, chronic arterial hypertension, both controlled KDIGO G5 chronic kidney disease on hemodialysis, and a body mass index of 36.72, furthermore has a family history of maternal left renal adenocarcinoma.

The patient presented with a five-week history characterized by chronic, non-productive cough and dyspnea without any specific time of day for symptom exacerbation. Physical examination revealed dullness to percussion and an absence of vesicular murmur in the left fifth and sixth intercostal spaces, consistent with fluid interposition syndrome, and a 3 cm diameter retroareolar mass in the left breast, non-mobile and petrous. A computed tomography (CT) scan incidentally detected a tumor with neoplastic features in the retroareolar region of the left breast. However, no significant findings are observed in the lung fields, mediastinum, or major vessels. Given the tumor’s characteristics, a more detailed imaging study was warranted. Breast magnetic resonance imaging (MRI) revealed irregular tissue with well-defined borders in the left retroareolar region (Figures 1A, 1B). Subsequent ultrasound reassessment confirmed the vascularity of the left breast nodule (Figure 1C), categorized as BI-RADS 4C.

Figure 1 (A,B) Magnetic resonance imaging and (C) ultrasound of the breast

(A,B) A hypodense lesion in the left breast suggestive of a nodule with irregular characteristics, angulated margins, and solid components.

(C) The nodule measures approximately 40.4 × 26.3 × 43 mm, showing penetrating vascularity on color Doppler and minimal acoustic enhancement.

Ultimately, the diagnosis was confirmed through an ultrasound-guided tru-cut biopsy. Histopathological examination revealed invasive mucinous carcinoma with over 50% mucin content within the tumor (Figures 2A, 2B). Immunohistochemical analysis indicated positivity for estrogen receptor, progesterone receptor, HER2/neu, and a Ki67 proliferation index of 60%, categorizing this breast cancer molecularly as luminal B HER2-positive subtype.

Figure 2 Histopathological findings of the left breast biopsy

(A) Low power (4×) view (white arrows) showing clusters of tumor cells immersed in a mucinous matrix.

(B) Medium power (10×) view showing neoplastic cells with round to oval nuclei and eosinophilic cytoplasm forming pseudoglandular structures within a mucinous background.

Once the diagnosis was confirmed, the oncology department proceeded with the standard laboratory analysis panel (Table 1). Significant findings included hypercalcemia, mild hypochloremia, elevated creatinine, hypochromic anemia, increased BUN, and slight thrombocytopenia; these abnormalities are attributable to the patient’s underlying chronic conditions.

Table 1 Laboratory tests performed with results and reference values

MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PTT, partial thromboplastin time; PT, prothrombin time

Laboratory test	Results	Reference range	
Hematocrit	34.1%	39-50%	
Hemoglobin	10.5 g/dL	13-17 g/dL	
Red blood cell (count)	4.47 10e6/µL	4-6.3 10e6/µL	
MCV	82.8 fL	72-96 fL	
MCH	25.9 pg	27-32 pg	
MCHC	30.8 g/dL	32-37 g/dL	
Lymphocytes (count)	1.59 10e3/µL	20-45 10e3/µL	
Lymphocytes %	17.2%	25-35%	
Neutrophils (count)	6.77 10e3/µL	5.5-6.5 10e3/µL	
Neutrophils %	73.4%	55-65%	
Eosinophils (count)	0.13 10e3/µL	3-5 10e3/µL	
Platelets	138 10e3/µL	150-500 10e3/µL	
RDW-CV	15.8%	11-16%	
RDW-SD	47.4%	37.2-54%	
Immature granulocytes	0%	0-2%	
Inorganic phosphorus	5.54 mg/dL	2.7-6.7 mg/dL	
Glucose	82.1 mg/dL	82-115 mg/dL	
Magnesium	2.19 mg/dL	1.63-2.41 mg/dL	
Blood urea nitrogen (BUN)	42.88 mg/dL	7.8-21.4 mg/dL	
Total urea	91.81 mg/dL	16.7-45.9 mg/dL	
Potassium	4.6 mmol/L	3.5-5.1 mmol/L	
Sodium	138.1 mmol/L	136-145 mmol/L	
Calcium	11.46 mg/dL	8.4-9.6 mg/dL	
AST	11.92 U/L	0-39 U/L	
ALT	5.6 U/L	7-63 U/L	
Total bilirubin	0.51 mg/dL	0-1 mg/dL	
PTT	11.5 sec	9.6-12 sec	
TPT	33.9 sec	22.7-32.5 sec	
Creatinine	8.87 mg/dL	0.7-1.2 mg/dL	

Staging studies revealed no evidence of metastasis, resulting in a clinical staging of T2N0MX. Radiographs of the upper limbs, spine, hips, and femur showed no abnormalities. A 2 cm diameter blastic lesion was identified in the frontal region of a skull radiograph, which, given the absence of nodal involvement and chronic kidney disease, was considered secondary to hyperparathyroidism. 

The patient underwent a modified radical left mastectomy (Figure 3A), with an excision of the mammary gland sent for pathology (Figure 3B). Intraoperative findings included a normal-sized left lymph node chain with no infiltration into the pectoral muscle, subcutaneous tissue, or skin. Subsequently, the patient was evaluated by gynecologic oncology for management due to his chronic kidney disease. Chemotherapy will not be administered, and the administration of tamoxifen was being considered; it has been decided to start solely with HER2 inhibitors to assess the patient’s tolerance. Subsequently, the possibility of introducing tamoxifen will be reassessed. The treatment consists of pertuzumab 420 mg and trastuzumab every 21 days for a total of 18 doses. Tumor markers such as cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CAE) will be used for monitoring. The five-year survival rate due to the cancer alone is 60%; however, the presence of associated comorbidities may worsen the prognosis.

Figure 3 (A) Preoperative findings of a 3 cm retroareolar tumor and (B) excision of the left mammary gland

Discussion

Embryologically, mammary glands originate from mesoderm and ectoderm, becoming epithelium and stroma, respectively. Males do not experience further breast development during puberty due to high testosterone levels but can undergo hormonal changes throughout life, expressing androgen, progesterone, and estrogen receptors [7,8].

Male breast cancer is a rare entity, with an estimated 2,800 new cases in the United States in 2024, representing only 0.5-1% of total diagnosed cases [9]. The American Cancer Society estimates that at least 530 American men will die from this condition. Black men continue to have higher incidence and worse outcomes [10].

We present a case of mucinous carcinoma diagnosed in Nicaragua, a country with a poor prognosis. Latin American countries with lower gross domestic product (GDP) (Honduras, Nicaragua, and Haiti) show one death per 2.5 cases, compared to the United States or Canada, where there is one death per 6.5 cases. This disparity can be attributed to the lack of access to quality healthcare, diagnostic tools, and top-tier therapy for much of our population [11].

This case offers an opportunity to study a rare histological subtype of breast carcinoma. Histologically, 80% of new cases are ductal carcinoma, with the remainder being lobular. Ductal carcinoma is divided into non-specific and specialized types, including medullary, metaplastic, apocrine, cribriform, tubular, pleomorphic, neuroendocrine, and the rare mucinous type [12].

Also known as mucinous or colloid carcinoma, this malignant neoplasm features epithelial cells with abundant extracellular mucin, hyperpigmented nuclei, and indistinguishable nucleoli. There are two types: the more frequent pure type, which must contain at least 90% mucin, subdivided into hypercellular (with tubular, cribriform, papillary, micropapillary, and cord growth patterns) and hypocellular (with a unique nest pattern), and the mixed type, which contains less mucin. The partial type includes 30-50% mucin, and the mixed proper type contains 50-90% mucin [13].

Macroscopically, its characteristics resemble a benign lesion, presenting as a palpable retroareolar mass with a texture like adipose tissue and defined margins [14].

The etiology is considered multifactorial, with significant risk factors in this case being age, excessive estrogen exposure, and genetics. 

Incidence varies by age group. A study of 10,596 patients diagnosed with mucinous carcinoma over 12 years found that the predominant age group was ≥60 years, representing 68% of the sample [15]. Komenaka et al. reviewed 65 cases of pure mucinous carcinoma, finding an average age of 67 years [16]. These reviews support that the most affected age group is ≥60 years, to which the patient in this case belongs. Only 1% of cases occur in individuals under 35 years [17].

The biological relationship between aging and cancer-associated cellular changes may explain this marked predisposition in older ages. The accumulation of senescent cells involves the gradual loss of homeostasis mechanisms, as many of these cells exhibit “senescence-associated secretory phenotypes,” capable of producing cytokines like IL-1, IL-2, IL-6, and IL-8, as well as proteases and growth factors, leading to a pro-inflammatory environment that affects metabolic and immune function. Additionally, older age correlates with more telomere shortening, more years of UV radiation exposure, and endogenous reactive oxygen species, contributing to a pro-carcinogenic environment [18]. 

Estrogens induce ductal mammary proliferation; hence, increased estrogen or decreased androgens can stimulate abnormal mammary growth. Conditions increasing estrogen include Klinefelter syndrome, obesity, endocrine disorders, liver dysfunction, and certain drugs. Pathologies decreasing androgens, such as cryptorchidism, orchiectomy, and hormone replacement, also lead to increased estrogens [19]. 

Genetics plays a significant role in male breast cancer development, with 20% of patients having a first-degree relative with breast cancer. A third of these cases involve BRCA1/2 mutations. Approximately 5-10% of men with BRCA2 develop breast cancer, compared to 1-2% with BRCA1. Interestingly, the phenotype of BRCA1/2-related breast cancers in men seems more aggressive than in women. The AR gene plays a role in the transformation of male breast epithelial cells into neoplasms, expressed in up to 74% of male breast cancer cases.

Imaging of male breast cancer typically includes mammography and breast ultrasound. Male breast carcinoma most commonly presents as a high-density irregular mass on mammography. Secondary findings include calcifications, skin thickening, nipple retraction, and axillary adenopathy. Ultrasonographic features of invasive ductal carcinoma in men include discrete hypoechoic masses [20].

Conclusions

Breast carcinoma in male patients, a rare condition predominantly affecting older men, poses distinctive challenges in both diagnosis and management, particularly magnified by healthcare access discrepancies evident in lower-income countries. This case study of mucinous carcinoma highlights the imperative of recognizing histological subtypes beyond the more prevalent ductal and lobular variants. The unique features of mucinous carcinoma, characterized by a mucin-rich cellular makeup and a macroscopic appearance akin to benign lesions, underscore the intricacies involved in early detection and precise diagnosis. Mucinous carcinoma is more prevalent among older individuals, indicating a significant age-related predisposition. Aging contributes to the accumulation of senescent cells and associated inflammatory responses, impacting cancer development. Understanding these age and molecular associations is critical for advancing targeted prevention and therapeutic strategies for affected populations.

Key imaging techniques such as breast MRI and ultrasound play a pivotal role in detecting these cancers early, providing essential insights into tumor characteristics that inform personalized treatment strategies. The incidental detection of the tumor in our case highlights the importance of comprehensive diagnostic assessments in male patients with unusual symptoms, guaranteeing prompt intervention and favorable results. Addressing disparities in male breast cancer outcomes between high- and low-GDP countries, such as Nicaragua, is crucial for improving global survival rates. The favorable intraoperative and postoperative outcomes observed in this patient following a modified radical mastectomy demonstrate the effectiveness of surgical intervention in managing male breast cancer.

Disclosures

Author Contributions

Human subjects: Consent was obtained or waived by all participants in this study.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Concept and design:  Gilberto A. Altamirano Sr., Christopher K. Romero, Catherine S. Moreno Cabrera , Lorenzo E. Aragón Conrado

Acquisition, analysis, or interpretation of data:  Gilberto A. Altamirano Sr., Christopher K. Romero, Catherine S. Moreno Cabrera , Lorenzo E. Aragón Conrado

Drafting of the manuscript:  Gilberto A. Altamirano Sr., Christopher K. Romero, Catherine S. Moreno Cabrera , Lorenzo E. Aragón Conrado

Critical review of the manuscript for important intellectual content:  Gilberto A. Altamirano Sr., Christopher K. Romero, Catherine S. Moreno Cabrera , Lorenzo E. Aragón Conrado

Supervision:  Gilberto A. Altamirano Sr.
==== Refs
References

1 Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program Ann Oncol Cardoso F Bartlett JM Slaets L 405 417 29 2018 29092024
2 Breast cancer in men N Engl J Med Giordano SH 2311 2320 378 2018 29897847
3 Favorable long-term outcome in male breast cancer Eur J Breast Health Özkurt E Tükenmez M Yılmaz R 180 185 14 2018 30123885
4 Male breast cancer: a review on diagnosis, treatment, and survivorship Curr Oncol Rep Bhardwaj PV Gupta S Elyash A Teplinsky E 34 45 26 2024 38224426
5 Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals J Clin Oncol Frank TS Deffenbaugh AM Reid JE 1480 1490 20 2002 11896095
6 Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas BMC Cancer Deb S Jene N Fox SB 510 12 2012 23146383
7 Male breast cancer: an update Virchows Arch Fox S Speirs V Shaaban AM 85 93 480 2022 34458944
8 Mucinous carcinoma in a male patient: diagnosis and management of breast cancer in male patients Radiol Case Rep Ahmed U Wagner S Jordan S 124 128 17 2022 34815818
9 Cancer statistics, 2024 CA Cancer J Clin Siegel RL Giaquinto AN Jemal A 12 49 74 2024 38230766
10 American Cancer Society. Cancer Facts & Figures 8 2024 2024 https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf
11 Organización Mundial De La Salud. Cáncer de mama en las Américas [Internet]. Organización Panamericana De La Salud 8 2024 2018 https://www.paho.org/sites/default/files/Cancer-mama-Americas-factsheet-ES%20%281%29.pdf
12 Histological, molecular and functional subtypes of breast cancers Cancer Biol Ther Malhotra GK Zhao X Band H Band V 955 960 10 2010 21057215
13 Clinicopathological and genomic features of breast mucinous carcinoma Breast Lu K Wang X Zhang W 130 137 53 2020 32781417
14 Mucinous breast cancer: a narrative review of the literature and a retrospective tertiary single-centre analysis Breast Marrazzo E Frusone F Milana F 87 92 49 2020 31783314
15 The clinical features and prognosis of patients with mucinous breast carcinoma compared with those with infiltrating ductal carcinoma: a population-based study BMC Cancer Zhou X Zheng Z Li Y Zhao W Lin Y Zhang J Sun Q 536 21 2021 33975551
16 Pure mucinous carcinoma of the breast Am J Surg Komenaka IK El-Tamer MB Troxel A 528 532 187 2004 15041505
17 Pure mucinous breast carcinoma in a 25-year-old female, a case report Int J Surg Case Rep Garcia-Hernandez I Lopez-Garcia CA Cardona-Huerta S 58 60 53 2018 30388613
18 Cancer and aging: two tightly interconnected biological processes Cancers (Basel) Berben L Floris G Wildiers H Hatse S 1400 13 2021 33808654
19 Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review Cancers (Basel) Łukasiewicz S Czeczelewski M Forma A Baj J Sitarz R Stanisławek A 4287 13 2021 34503097
20 Synchronous bilateral breast cancer: a first case with lobular and mucinous carcinoma Radiol Case Rep El Amrani S Hiba Z Hosni A Omor Y Latib R 3218 3222 18 2023 37448601
